首页 > 最新文献

General hospital psychiatry最新文献

英文 中文
Psychological support can be distinguished from psychotherapy: Clarifications for future empirical work 心理支持可以区别于心理治疗:对未来实证工作的澄清
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-29 DOI: 10.1016/j.genhosppsych.2025.12.021
Jonathan R. Schettino , Katherine Cheung , Sandeep M. Nayak , Brandon M. Weiss , David B. Yaden
Classic psychedelic studies involve interpersonal interactions with participants before, during, and after the acute effects of psychedelics. In the field of psychedelic research, there is currently a debate about whether this interpersonal interaction is most accurately considered “psychological support,” “psychotherapy,” or something else. Proponents of the psychological support label describe the interpersonal interaction in most classic psychedelic studies as aimed at safety, while proponents of the psychotherapy label argue that the interpersonal interaction involves intervening on psychotherapeutic processes that not only support safety, but also contribute to treatment efficacy. However, we believe that the debate has so far been largely unproductive due to a lack of shared definitions or criteria for the relevant interpersonal interactions. Here, we propose definitions and criteria for two viable forms of interpersonal interaction in psychedelic administration: one directed solely towards safety (psychological support) and one directed towards both safety and efficacy (psychotherapy). We then trial our proposed criteria on a sample of 11 published classic psychedelic clinical trials. Our procedure categorized 10 out of 11 studies as being more or less consistent with psychological support or psychotherapy, but achieved clear distinctions in only 4 out of 11 studies. Given these findings, we argue that higher quality data on the interpersonal interaction is needed to clearly distinguish between psychological support and psychotherapy. We conclude by suggesting ways that our criteria can be used in the future to empirically test the relative safety and efficacy of psychological support vs. psychotherapy in psychedelic medicine.
经典的迷幻药研究包括在迷幻药产生急性效应之前、期间和之后与参与者的人际互动。在迷幻药研究领域,目前存在一种争论,即这种人际互动是否更准确地被认为是“心理支持”、“心理治疗”或其他什么。心理支持标签的支持者将大多数经典迷幻研究中的人际互动描述为旨在安全,而心理治疗标签的支持者则认为,人际互动涉及对心理治疗过程的干预,这不仅支持安全,而且有助于治疗效果。然而,我们认为,由于缺乏有关人际交往的共同定义或标准,迄今为止的辩论在很大程度上是无效的。在这里,我们提出了迷幻药管理中两种可行的人际互动形式的定义和标准:一种只针对安全性(心理支持),另一种针对安全性和有效性(心理治疗)。然后,我们在11个已发表的经典迷幻药临床试验样本上试用我们提出的标准。我们的程序将11项研究中的10项分类为或多或少与心理支持或心理治疗一致,但在11项研究中只有4项获得了明确的区别。鉴于这些发现,我们认为需要更高质量的人际互动数据来明确区分心理支持和心理治疗。最后,我们提出了一些方法,我们的标准可以在未来用于对迷幻药物中心理支持与心理治疗的相对安全性和有效性进行实证测试。
{"title":"Psychological support can be distinguished from psychotherapy: Clarifications for future empirical work","authors":"Jonathan R. Schettino ,&nbsp;Katherine Cheung ,&nbsp;Sandeep M. Nayak ,&nbsp;Brandon M. Weiss ,&nbsp;David B. Yaden","doi":"10.1016/j.genhosppsych.2025.12.021","DOIUrl":"10.1016/j.genhosppsych.2025.12.021","url":null,"abstract":"<div><div>Classic psychedelic studies involve interpersonal interactions with participants before, during, and after the acute effects of psychedelics. In the field of psychedelic research, there is currently a debate about whether this interpersonal interaction is most accurately considered “psychological support,” “psychotherapy,” or something else. Proponents of the psychological support label describe the interpersonal interaction in most classic psychedelic studies as aimed at safety, while proponents of the psychotherapy label argue that the interpersonal interaction involves intervening on psychotherapeutic processes that not only support safety, but also contribute to treatment efficacy. However, we believe that the debate has so far been largely unproductive due to a lack of shared definitions or criteria for the relevant interpersonal interactions. Here, we propose definitions and criteria for two viable forms of interpersonal interaction in psychedelic administration: one directed solely towards safety (psychological support) and one directed towards both safety and efficacy (psychotherapy). We then trial our proposed criteria on a sample of 11 published classic psychedelic clinical trials. Our procedure categorized 10 out of 11 studies as being more or less consistent with psychological support or psychotherapy, but achieved clear distinctions in only 4 out of 11 studies. Given these findings, we argue that higher quality data on the interpersonal interaction is needed to clearly distinguish between psychological support and psychotherapy. We conclude by suggesting ways that our criteria can be used in the future to empirically test the relative safety and efficacy of psychological support vs. psychotherapy in psychedelic medicine.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"99 ","pages":"Pages 30-40"},"PeriodicalIF":3.7,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Readmission rates following repetitive transcranial magnetic stimulation (rTMS) for post-traumatic stress disorder with comorbid major depressive disorder 重复经颅磁刺激(rTMS)治疗创伤后应激障碍伴重性抑郁症的再入院率
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-23 DOI: 10.1016/j.genhosppsych.2025.12.018
Natalie Seiler , Thomas P. Nguyen , Amy Coelen , Benjamin Newham , Timothy Rolfe
{"title":"Readmission rates following repetitive transcranial magnetic stimulation (rTMS) for post-traumatic stress disorder with comorbid major depressive disorder","authors":"Natalie Seiler ,&nbsp;Thomas P. Nguyen ,&nbsp;Amy Coelen ,&nbsp;Benjamin Newham ,&nbsp;Timothy Rolfe","doi":"10.1016/j.genhosppsych.2025.12.018","DOIUrl":"10.1016/j.genhosppsych.2025.12.018","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 148-150"},"PeriodicalIF":3.7,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between recency of suicide attempt and reattempt in adult emergency department patients 成人急诊科病人自杀企图与再企图的关系
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-20 DOI: 10.1016/j.genhosppsych.2025.12.017
Tesia Shi , Ritika Merai , Cristan Farmer , August Wei , Ivan W. Miller , Carlos A. Camargo Jr , Maryland Pao , Jeffrey A. Bridge , Edwin D. Boudreaux , Lisa M. Horowitz
{"title":"The association between recency of suicide attempt and reattempt in adult emergency department patients","authors":"Tesia Shi ,&nbsp;Ritika Merai ,&nbsp;Cristan Farmer ,&nbsp;August Wei ,&nbsp;Ivan W. Miller ,&nbsp;Carlos A. Camargo Jr ,&nbsp;Maryland Pao ,&nbsp;Jeffrey A. Bridge ,&nbsp;Edwin D. Boudreaux ,&nbsp;Lisa M. Horowitz","doi":"10.1016/j.genhosppsych.2025.12.017","DOIUrl":"10.1016/j.genhosppsych.2025.12.017","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 157-158"},"PeriodicalIF":3.7,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to letter to the editor on methodological and biological considerations for interpreting statin–depression associations 回复致编辑的关于解释他汀类药物与抑郁相关的方法学和生物学考虑的信函
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-18 DOI: 10.1016/j.genhosppsych.2025.12.015
Tzu-Rong Peng , Pei-Yun Tsai , Jen-Ai Lee
{"title":"Response to letter to the editor on methodological and biological considerations for interpreting statin–depression associations","authors":"Tzu-Rong Peng ,&nbsp;Pei-Yun Tsai ,&nbsp;Jen-Ai Lee","doi":"10.1016/j.genhosppsych.2025.12.015","DOIUrl":"10.1016/j.genhosppsych.2025.12.015","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 136-137"},"PeriodicalIF":3.7,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145787391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does therapeutic alliance exist in team-based hospital settings? A qualitative study in complex continuing care 在以团队为基础的医院环境中是否存在治疗联盟?复杂持续护理的定性研究
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-18 DOI: 10.1016/j.genhosppsych.2025.12.016
Jon Hunter , Mary Zheng , Lianne Jeffs , Baieruss Trinos , Nicole Allard , Aine O'Sullivan , Lily Zeng , Rebecca Ramsden , Jordan Pelc
Therapeutic Alliance is a measurable construct reflecting patient-provider relationships. It is known to predict important healthcare outcomes in both the mental health and general medical contexts. However, it has not been validated in team-based healthcare settings, such as hospitals. Complex Continuing Care (CCC) is a chronic-care hospital setting that manages patients with significant multi-morbidity and extensive nursing care needs, beyond the capacity of long-term care. The combination of long lengths of stay and very large health-care teams make CCC an environment where patient-provider relationships are a prominent part of the healthcare experience. We sought therefore to explore therapeutic relationships in CCC, using a qualitative approach to determine whether patients experience team-based care as a collection of individual therapeutic relationships, for which alliance could be measured, or conversely whether they experience team-based care as a diffuse, team-based relationship to which individual therapeutic alliances as currently understood do not apply. To do so, we interviewed 16 CCC patients using a semi-structured format. Interviews were transcribed and analyzed via qualitative analysis. This analysis revealed that the predominant emphasis was upon 1:1 relationships with healthcare providers as most determinant of care experience, with little emphasis on diffuse or team-based relationships. This study shows that in a setting of high clinical complexity, despite care being delivered by a large team of multiple disciplines, the centrality of 1:1 relationships between patients and their clinicians was paramount, providing the first-ever qualitative evidence for the validity of therapeutic alliance in the team-based setting.
治疗联盟是一种可测量的结构,反映了患者与提供者的关系。众所周知,它可以预测心理健康和一般医疗环境中的重要医疗保健结果。然而,它尚未在基于团队的医疗保健环境(如医院)中得到验证。复杂持续护理(CCC)是一种慢性护理医院环境,用于管理严重多发性疾病和广泛护理需求的患者,超出了长期护理的能力。长时间的住院和非常大的医疗保健团队的结合使CCC成为一个患者-提供者关系是医疗保健体验的重要组成部分的环境。因此,我们试图探索CCC中的治疗关系,使用定性方法来确定患者是否将团队护理作为个体治疗关系的集合,可以测量其联盟,或者相反,他们是否将团队护理作为分散的,团队为基础的关系,目前所理解的个体治疗联盟不适用。为此,我们使用半结构化格式采访了16例CCC患者。访谈记录并通过定性分析进行分析。该分析显示,主要强调与医疗保健提供者的1:1关系是护理经验的最决定因素,很少强调分散或基于团队的关系。本研究表明,在临床高度复杂的环境中,尽管护理是由多学科的大型团队提供的,但患者和临床医生之间1:1关系的中心性至关重要,为团队为基础的治疗联盟的有效性提供了第一个定性证据。
{"title":"Does therapeutic alliance exist in team-based hospital settings? A qualitative study in complex continuing care","authors":"Jon Hunter ,&nbsp;Mary Zheng ,&nbsp;Lianne Jeffs ,&nbsp;Baieruss Trinos ,&nbsp;Nicole Allard ,&nbsp;Aine O'Sullivan ,&nbsp;Lily Zeng ,&nbsp;Rebecca Ramsden ,&nbsp;Jordan Pelc","doi":"10.1016/j.genhosppsych.2025.12.016","DOIUrl":"10.1016/j.genhosppsych.2025.12.016","url":null,"abstract":"<div><div>Therapeutic Alliance is a measurable construct reflecting patient-provider relationships. It is known to predict important healthcare outcomes in both the mental health and general medical contexts. However, it has not been validated in team-based healthcare settings, such as hospitals. Complex Continuing Care (CCC) is a chronic-care hospital setting that manages patients with significant multi-morbidity and extensive nursing care needs, beyond the capacity of long-term care. The combination of long lengths of stay and very large health-care teams make CCC an environment where patient-provider relationships are a prominent part of the healthcare experience. We sought therefore to explore therapeutic relationships in CCC, using a qualitative approach to determine whether patients experience team-based care as a collection of individual therapeutic relationships, for which alliance could be measured, or conversely whether they experience team-based care as a diffuse, team-based relationship to which individual therapeutic alliances as currently understood do not apply. To do so, we interviewed 16 CCC patients using a semi-structured format. Interviews were transcribed and analyzed via qualitative analysis. This analysis revealed that the predominant emphasis was upon 1:1 relationships with healthcare providers as most determinant of care experience, with little emphasis on diffuse or team-based relationships. This study shows that in a setting of high clinical complexity, despite care being delivered by a large team of multiple disciplines, the centrality of 1:1 relationships between patients and their clinicians was paramount, providing the first-ever qualitative evidence for the validity of therapeutic alliance in the team-based setting.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 151-156"},"PeriodicalIF":3.7,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of depressive episodes with mixed features: A systematic review and meta-analysis 混合特征抑郁发作的治疗:系统回顾和荟萃分析
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-17 DOI: 10.1016/j.genhosppsych.2025.12.011
Francisco Villalón , Rodolfo Philippi , Fabio Mendoza

Background

Depressive episodes with concurrent manic or hypomanic symptoms—i.e., depressive episodes with mixed features—are common in bipolar disorder and are associated with greater chronicity, functional impairment, and suicide risk. However, treatment guidance remains limited and inconsistent.

Objective

To systematically review and perform a stratified meta-analysis of pharmacological and non-pharmacological interventions for depressive episodes with mixed features, distinguishing randomized controlled trials (RCTs) from non-RCTs and assessing risk of bias.

Methods

A systematic review was conducted in accordance with the PRISMA 2020 guidelines. MEDLINE, CINAHL Complete, Epistemonikos, and ClinicalTrials.gov were systematically searched between July and November 2024 without language restrictions (PROSPERO CRD42025644083). Eligible studies included adults with bipolar depression and mixed features. Two reviewers independently screened, extracted data, and assessed bias. Standardized mean differences (SMD, Hedges' g) were pooled using random-effects models with Hartung–Knapp adjustment. RCTs were not combined with non-RCTs.

Results

Twenty-two studies (n = 3525) met inclusion: five parallel RCTs, one crossover RCT, five pooled analyses, nine post-hoc studies, and two quasi-experimental designs. Among RCTs, antipsychotic treatments demonstrated efficacy with low heterogeneity (pooled SMD –0.70; I2 = 0.0 %). Single RCTs of lurasidone (SMD –0.80) and ziprasidone (SMD –0.70) showed improvement versus placebo; lumateperone yielded a moderate effect (SMD –0.64). Celecoxib and theta-burst stimulation were not superior to placebo. Non-RCTs of antipsychotics showed smaller effects with substantial heterogeneity (SMD –0.55; I2 = 81.7 %).

Conclusions

Limited but consistent RCT evidence supports lurasidone and ziprasidone for mixed-feature depression, while other interventions showed no clear benefit. Standardized diagnostic definitions and additional high-quality trials are essential to refine therapeutic recommendations and reduce heterogeneity.
背景:伴有躁狂或轻躁狂症状的抑郁发作。具有混合特征的抑郁发作在双相情感障碍中很常见,并且与更大的慢性、功能损害和自杀风险相关。然而,治疗指导仍然有限且不一致。目的系统回顾并对具有混合特征的抑郁发作的药物和非药物干预进行分层荟萃分析,区分随机对照试验(rct)和非rct,并评估偏倚风险。方法按照PRISMA 2020指南进行系统评价。在2024年7月至11月间系统检索MEDLINE、CINAHL Complete、Epistemonikos和ClinicalTrials.gov,没有语言限制(PROSPERO CRD42025644083)。符合条件的研究包括患有双相抑郁症和混合特征的成年人。两位审稿人独立筛选、提取数据并评估偏倚。标准化平均差异(SMD, Hedges' g)采用Hartung-Knapp调整的随机效应模型进行汇总。随机对照试验未与非随机对照试验合并。结果共纳入22项研究(n = 3525): 5项平行随机对照试验、1项交叉随机对照试验、5项合并分析、9项事后研究和2项准实验设计。在随机对照试验中,抗精神病药物治疗显示出低异质性的疗效(合并SMD = 0.70; I2 = 0.0%)。鲁拉西酮(SMD -0.80)和齐拉西酮(SMD -0.70)的单次rct与安慰剂相比显示改善;lumateperone产生中等效果(SMD -0.64)。塞来昔布和脉冲刺激并不优于安慰剂。抗精神病药物的非随机对照试验显示效果较小,且异质性显著(SMD -0.55; I2 = 81.7%)。结论有限但一致的RCT证据支持鲁拉西酮和齐拉西酮治疗混合特征抑郁症,而其他干预措施没有明显的益处。标准化的诊断定义和额外的高质量试验对于完善治疗建议和减少异质性至关重要。
{"title":"Treatment of depressive episodes with mixed features: A systematic review and meta-analysis","authors":"Francisco Villalón ,&nbsp;Rodolfo Philippi ,&nbsp;Fabio Mendoza","doi":"10.1016/j.genhosppsych.2025.12.011","DOIUrl":"10.1016/j.genhosppsych.2025.12.011","url":null,"abstract":"<div><h3>Background</h3><div>Depressive episodes with concurrent manic or hypomanic symptoms—i.e., depressive episodes with mixed features—are common in bipolar disorder and are associated with greater chronicity, functional impairment, and suicide risk. However, treatment guidance remains limited and inconsistent.</div></div><div><h3>Objective</h3><div>To systematically review and perform a stratified meta-analysis of pharmacological and non-pharmacological interventions for depressive episodes with mixed features, distinguishing randomized controlled trials (RCTs) from non-RCTs and assessing risk of bias.</div></div><div><h3>Methods</h3><div>A systematic review was conducted in accordance with the PRISMA 2020 guidelines. MEDLINE, CINAHL Complete, Epistemonikos, and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> were systematically searched between July and November 2024 without language restrictions (PROSPERO CRD42025644083). Eligible studies included adults with bipolar depression and mixed features. Two reviewers independently screened, extracted data, and assessed bias. Standardized mean differences (SMD, Hedges' g) were pooled using random-effects models with Hartung–Knapp adjustment. RCTs were not combined with non-RCTs.</div></div><div><h3>Results</h3><div>Twenty-two studies (<em>n</em> = 3525) met inclusion: five parallel RCTs, one crossover RCT, five pooled analyses, nine post-hoc studies, and two quasi-experimental designs. Among RCTs, antipsychotic treatments demonstrated efficacy with low heterogeneity (pooled SMD –0.70; I<sup>2</sup> = 0.0 %). Single RCTs of lurasidone (SMD –0.80) and ziprasidone (SMD –0.70) showed improvement versus placebo; lumateperone yielded a moderate effect (SMD –0.64). Celecoxib and theta-burst stimulation were not superior to placebo. Non-RCTs of antipsychotics showed smaller effects with substantial heterogeneity (SMD –0.55; I<sup>2</sup> = 81.7 %).</div></div><div><h3>Conclusions</h3><div>Limited but consistent RCT evidence supports lurasidone and ziprasidone for mixed-feature depression, while other interventions showed no clear benefit. Standardized diagnostic definitions and additional high-quality trials are essential to refine therapeutic recommendations and reduce heterogeneity.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 126-135"},"PeriodicalIF":3.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145787289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paraquat regulation as a suicide prevention strategy in India 百草枯法规在印度作为自杀预防策略
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-16 DOI: 10.1016/j.genhosppsych.2025.12.012
Jawahar Singh, Mahak Aggarwal, Deepak Chaudhary, Bharat Udey
Paraquat is a lethal herbicide that is emerging as a significant means of self-harm/suicide in agrarian regions of India. Clinical experience from a tertiary hospital in Punjab shows increasing paraquat ingestion cases with high mortality despite early, intensive management. National and international evidence indicates that restricting highly hazardous pesticides (HHPs) markedly reduces suicide deaths, yet paraquat remains easily accessible due to weak regulation and unsafe storage in rural communities. Stronger regulation and classifying paraquat as an HHP can be an essential step toward reducing preventable suicides in India.
百草枯是一种致命的除草剂,正在成为印度农业地区自残/自杀的重要手段。旁遮普省一家三级医院的临床经验表明,尽管进行了早期强化管理,但摄入百草枯的病例仍在增加,死亡率很高。国家和国际证据表明,限制高度危险农药可显著减少自杀死亡,但由于监管不力和农村社区储存不安全,百草枯仍然很容易获得。加强监管和将百草枯归类为高致病性农药是印度减少可预防自杀的重要一步。
{"title":"Paraquat regulation as a suicide prevention strategy in India","authors":"Jawahar Singh,&nbsp;Mahak Aggarwal,&nbsp;Deepak Chaudhary,&nbsp;Bharat Udey","doi":"10.1016/j.genhosppsych.2025.12.012","DOIUrl":"10.1016/j.genhosppsych.2025.12.012","url":null,"abstract":"<div><div>Paraquat is a lethal herbicide that is emerging as a significant means of self-harm/suicide in agrarian regions of India. Clinical experience from a tertiary hospital in Punjab shows increasing paraquat ingestion cases with high mortality despite early, intensive management. National and international evidence indicates that restricting highly hazardous pesticides (HHPs) markedly reduces suicide deaths, yet paraquat remains easily accessible due to weak regulation and unsafe storage in rural communities. Stronger regulation and classifying paraquat as an HHP can be an essential step toward reducing preventable suicides in India.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 84-85"},"PeriodicalIF":3.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145787290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of mindfulness-based interventions (MBIs) on headache pain in migraine patients: A systematic review and meta-analysis 正念干预(MBIs)对偏头痛患者头痛的影响:系统回顾和荟萃分析
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-16 DOI: 10.1016/j.genhosppsych.2025.12.013
Chuntana Reangsing , Sasinun Punsuwun , Sarah Oerther

Objective

We synthesized the effects of mindfulness-based interventions (MBIs) on headache pain in migraine patients and conducted moderator analyses to identify the sources of heterogeneity.

Methods

We searched nine databases from their inception until November 2024. Our focus was on primary studies that compared MBIs with waitlist, usual care, or no intervention in terms of improving headache pain in patients with migraines. We only included studies published in English. A random-effects model was employed to calculate the effect size (ES). We used a funnel plot, Q statistics, and the I2 statistic to assess the heterogeneity among the studies. Additionally, we performed moderator analyses to investigate the sources of heterogeneity based on the information source, methods used, intervention specifics, and participant characteristics.

Results

In a review of 10 primary studies involving 330 patients with migraines, 319 patients served as controls. The participants' mean age ranged from 31.15 to 46.77 years. Overall, the findings indicated that mindfulness-based interventions (MBIs) significantly reduced headache pain in the MBI groups compared to the control groups, with a Hedge's g of 0.389 (95 % Confidence Interval [CI]: 0.126, 0.651) and an I2 value of 61.3 %. Moderator analyses revealed that the intention-to-treat technique and the power of sample influenced the effect sizes. No other quality indicators were found to moderate the effect sizes.

Conclusion

MBIs have shown effectiveness in reducing headache pain in migraines patients. Clinicians and health professionals should consider utilizing MBIs as alternative or complementary treatments to reduce the severity of headaches in these patients.
目的综合正念干预(mbi)对偏头痛患者头痛的影响,并进行调节分析以确定异质性的来源。方法我们检索了9个数据库,从数据库建立到2024年11月。我们的重点是比较mbi与候补治疗、常规治疗或无干预治疗在改善偏头痛患者头痛方面的初步研究。我们只纳入了用英语发表的研究。采用随机效应模型计算效应量(ES)。我们使用漏斗图、Q统计量和I2统计量来评估研究之间的异质性。此外,我们根据信息源、使用的方法、干预细节和参与者特征进行了调节分析,以调查异质性的来源。结果回顾了10项涉及330例偏头痛患者的初步研究,其中319例患者作为对照。参与者的平均年龄从31.15岁到46.77岁不等。总体而言,研究结果表明,与对照组相比,正念干预(MBI)显著减少了MBI组的头痛,其对冲系数g为0.389(95%可信区间[CI]: 0.126, 0.651), I2值为61.3%。调节分析显示,意向治疗技术和样本的力量影响效应大小。没有发现其他质量指标可以调节效应大小。结论mbis能有效减轻偏头痛患者的头痛。临床医生和卫生专业人员应考虑使用MBIs作为替代或补充治疗,以减轻这些患者头痛的严重程度。
{"title":"Effects of mindfulness-based interventions (MBIs) on headache pain in migraine patients: A systematic review and meta-analysis","authors":"Chuntana Reangsing ,&nbsp;Sasinun Punsuwun ,&nbsp;Sarah Oerther","doi":"10.1016/j.genhosppsych.2025.12.013","DOIUrl":"10.1016/j.genhosppsych.2025.12.013","url":null,"abstract":"<div><h3>Objective</h3><div>We synthesized the effects of mindfulness-based interventions (MBIs) on headache pain in migraine patients and conducted moderator analyses to identify the sources of heterogeneity.</div></div><div><h3>Methods</h3><div>We searched nine databases from their inception until November 2024. Our focus was on primary studies that compared MBIs with waitlist, usual care, or no intervention in terms of improving headache pain in patients with migraines. We only included studies published in English. A random-effects model was employed to calculate the effect size (ES). We used a funnel plot, Q statistics, and the I<sup>2</sup> statistic to assess the heterogeneity among the studies. Additionally, we performed moderator analyses to investigate the sources of heterogeneity based on the information source, methods used, intervention specifics, and participant characteristics.</div></div><div><h3>Results</h3><div>In a review of 10 primary studies involving 330 patients with migraines, 319 patients served as controls. The participants' mean age ranged from 31.15 to 46.77 years. Overall, the findings indicated that mindfulness-based interventions (MBIs) significantly reduced headache pain in the MBI groups compared to the control groups, with a Hedge's g of 0.389 (95 % Confidence Interval [CI]: 0.126, 0.651) and an I<sup>2</sup> value of 61.3 %. Moderator analyses revealed that the intention-to-treat technique and the power of sample influenced the effect sizes. No other quality indicators were found to moderate the effect sizes.</div></div><div><h3>Conclusion</h3><div>MBIs have shown effectiveness in reducing headache pain in migraines patients. Clinicians and health professionals should consider utilizing MBIs as alternative or complementary treatments to reduce the severity of headaches in these patients.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 107-115"},"PeriodicalIF":3.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145787301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice 致幻剂治疗的资格:临床试验医学排除标准及其对医院实践的影响
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-16 DOI: 10.1016/j.genhosppsych.2025.12.009
Martin L. Williams , Karen Hitchcock , Angus H. Miller , Simon A. Beck
Clinical research in psychedelic-assisted therapies is flourishing following the resumption of human trials exploring classic psychedelics and their therapeutic application to a range of mental health conditions. Translation from research to the clinic is underway in Australia and appears imminent in several other countries. Classic psychedelics function primarily as agonists of a subgroup of serotonin (5-HT) receptors but also act to varying degrees at other receptor and transporter systems. Some physiological responses to psychedelics may present risks to susceptible individuals that must be weighed against the potential neuropsychological benefits afforded by psychedelic therapies. Hence, an important rationale for eligibility criteria in clinical trials is to ensure participant safety by minimizing risks of adverse events. The analysis presented here focuses on physiological considerations associated with psychedelic therapies. We conducted a critical evaluation of medical exclusion criteria applied in clinical studies of psychedelic-assisted therapy listed on international clinical trials registries. The criteria were interrogated for their rationale and medical basis; informed by this analysis, the evolution of medical exclusion criteria over twenty-five years of psychedelic clinical research was considered. Finally, the applicability of medical exclusion criteria in psychedelic therapies is discussed in the context of hospital-based psychiatry as the global transition from clinical trials to clinical practice gathers pace.
随着探索经典致幻剂及其对一系列精神健康状况的治疗应用的人体试验的恢复,致幻剂辅助疗法的临床研究正在蓬勃发展。澳大利亚正在进行从研究到临床的转化,其他几个国家似乎也即将进行。经典致幻剂主要作为5-羟色胺(5-HT)受体亚群的激动剂起作用,但也不同程度地作用于其他受体和转运体系统。对致幻剂的一些生理反应可能会给易感个体带来风险,必须与致幻剂治疗所带来的潜在神经心理学益处进行权衡。因此,临床试验资格标准的一个重要依据是通过最小化不良事件的风险来确保参与者的安全。本文的分析侧重于与迷幻药治疗相关的生理因素。我们对国际临床试验注册中列出的用于迷幻剂辅助治疗临床研究的医学排除标准进行了严格的评估。对这些标准的理由和医学依据进行了讯问;根据这一分析,考虑了25年来致幻剂临床研究中医学排除标准的演变。最后,随着全球从临床试验到临床实践的转变步伐加快,在以医院为基础的精神病学背景下,讨论了药物排除标准在致幻剂治疗中的适用性。
{"title":"Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice","authors":"Martin L. Williams ,&nbsp;Karen Hitchcock ,&nbsp;Angus H. Miller ,&nbsp;Simon A. Beck","doi":"10.1016/j.genhosppsych.2025.12.009","DOIUrl":"10.1016/j.genhosppsych.2025.12.009","url":null,"abstract":"<div><div>Clinical research in psychedelic-assisted therapies is flourishing following the resumption of human trials exploring classic psychedelics and their therapeutic application to a range of mental health conditions. Translation from research to the clinic is underway in Australia and appears imminent in several other countries. Classic psychedelics function primarily as agonists of a subgroup of serotonin (5-HT) receptors but also act to varying degrees at other receptor and transporter systems. Some physiological responses to psychedelics may present risks to susceptible individuals that must be weighed against the potential neuropsychological benefits afforded by psychedelic therapies. Hence, an important rationale for eligibility criteria in clinical trials is to ensure participant safety by minimizing risks of adverse events. The analysis presented here focuses on physiological considerations associated with psychedelic therapies. We conducted a critical evaluation of medical exclusion criteria applied in clinical studies of psychedelic-assisted therapy listed on international clinical trials registries. The criteria were interrogated for their rationale and medical basis; informed by this analysis, the evolution of medical exclusion criteria over twenty-five years of psychedelic clinical research was considered. Finally, the applicability of medical exclusion criteria in psychedelic therapies is discussed in the context of hospital-based psychiatry as the global transition from clinical trials to clinical practice gathers pace.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 116-125"},"PeriodicalIF":3.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145787298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatry coordination team: A systematic and comprehensive approach to inpatient psychiatry referral management 精神病学协调小组:一种系统、全面的住院精神病学转诊管理方法。
IF 3.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-16 DOI: 10.1016/j.genhosppsych.2025.12.014
Michael T. Kane , Evan M. Vitiello , Riah Patterson , Mandy Chavis , Dee Dee Fryer , Barbara-Ann Bybel , Kenan Penaskovic
{"title":"Psychiatry coordination team: A systematic and comprehensive approach to inpatient psychiatry referral management","authors":"Michael T. Kane ,&nbsp;Evan M. Vitiello ,&nbsp;Riah Patterson ,&nbsp;Mandy Chavis ,&nbsp;Dee Dee Fryer ,&nbsp;Barbara-Ann Bybel ,&nbsp;Kenan Penaskovic","doi":"10.1016/j.genhosppsych.2025.12.014","DOIUrl":"10.1016/j.genhosppsych.2025.12.014","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"98 ","pages":"Pages 138-139"},"PeriodicalIF":3.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
General hospital psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1